KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2023 value amounting to 0.17%.

  • AbCellera Biologics' Return on Capital Employed fell 3200.0% to 0.17% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.17%, marking a year-over-year decrease of 3200.0%. This contributed to the annual value of 0.23% for FY2024, which is 600.0% down from last year.
  • Latest data reveals that AbCellera Biologics reported Return on Capital Employed of 0.17% as of Q4 2023, which was down 3200.0% from 0.15% recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Return on Capital Employed ranged from a high of 0.32% in Q1 2021 and a low of 0.17% during Q4 2023
  • Moreover, its 3-year median value for Return on Capital Employed was 0.19% (2021), whereas its average is 0.12%.
  • In the last 5 years, AbCellera Biologics' Return on Capital Employed plummeted by -300bps in 2022 and then crashed by -3800bps in 2023.
  • Over the past 3 years, AbCellera Biologics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then fell by -17bps to 0.15% in 2022, then tumbled by -213bps to 0.17% in 2023.
  • Its last three reported values are 0.17% in Q4 2023, 0.15% for Q3 2023, and 0.08% during Q2 2023.